Biogen Stock News

Save(0) Please login to bookmark Username or Email Address Password Remember Me Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a [] Subscribe for instant access to all Lawyerly content. Already a subscriber? Username or Email Address Password Remember Me Lost your password? Want to test drive Lawyerly? Contact us to take a free trial. The post Biogen may sue third generic drug maker to protect MS drug Tecfidera appeared first on Lawyerly .

Following up on my post last week (Dec 1.), I have read commentary about how the Federal Circuit''s decision in Biogen v. Mylan was incorrect.

How did the Aduhelm debacle push Biogen to the brink? And what''s the latest on Omicron? All that and more on the latest episode of "The Readout LOUD." Listen now:

Traynor Capital Management Inc. decreased its position in Biogen Inc. (NASDAQ:BIIB) by 9.4% during the 3rd quarter, Holdings Channel reports. The fund owned 22,730 shares of the biotechnology companys stock after selling 2,353 shares during the quarter. Biogen comprises about 0.9% of Traynor Capital Management Inc.s holdings, making the stock its 25th biggest position. Traynor []

The lymphoproliferative Disorder therapie market contains of sales of lymphoproliferative Disorder therapie goods and related facilities for neurodegenerative disorders. Neurodegenerative disorder is a range of inveterate conditions that mainly affect the nerve cell of the human brain and consequences in

The Goldman Sachs Group began coverage on shares of Biogen (NASDAQ:BIIB) in a research report report published on Monday morning, Analyst Price Targets reports. The brokerage issued a neutral rating and a $271.00 target price on the biotechnology companys stock. Other equities analysts have also recently issued research reports about the company. Barclays dropped their []

Biogen is preparing for its largest-ever layoff in which more than 1,000 employees are expected to lose their jobs after the disastrous launch of Aduhelm.

The "Halftime Report" traders answer viewer questions in #AskHalftime. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi  » Subscribe to CNBC TV: https:/

Check out these biotech stocks turning heads in the stock market now.

(RTTNews) - Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that new analyses from the landscape clinical development program of zuranolone in major depressive disorder or MDD were presented at the American College Of Neuropsychopharmacology Congress. Data from the SHORELINE and WATERFALL Studies in the LANDSCAPE clinical program

The global Peripheral Neuropathy Treatment market is expected a CAGR of 5.8% from 2021 to 2027. Major players are concentrating their efforts on developing drugs to treat peripheral neuropathy, which is expected to drive market growth during the forecast period.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE clinical program evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder (MDD) presented at the American College of Neuropsychopharmacology (ACNP) Congress taking place December 5-8 in San Juan, Puerto Rico. Data from the SHORELINE and WATERFALL Studies in the LANDSCAPE clinical program further the understand

Aduhelm was the tipping point for Biogen''s turmoil, but STAT''s reporting reveals much deeper problems at the company, rooted in years of corporate tension and bitter disputes about its strategic